On September 8, 2026, Indaptus Therapeutics, Inc. entered into a Stock Purchase Agreement to issue and sell 20,338,974 shares of common stock in a private placement for aggregate gross proceeds of approximately $24.0 million. The purchase price per share equals the Nasdaq Minimum Price plus $0.015, where the Nasdaq Minimum Price is the lower of the prior day's closing price or the five-day average closing price. Net proceeds are intended for working capital, research and development, and general corporate purposes, including early-stage evaluation of a potential neurotechnology device for sleep-related conditions with a view toward future FDA submission. The closing is subject to customary conditions and must occur within fifteen business days following September 8, 2026. Indaptus Therapeutics operates in the biotechnology industry, focusing on developing treatments for neurological disorders.
